The effectiveness and safety of docetaxel+cisplatin chemotherapy combined with concurrent surgery in the treatment of patients with coronary heart disease and lung cancer
Objective To study the effectiveness and safety of docetaxel+cisplatin chemotherapy combined with concurrent surgery in the treatment of patients with coronary heart disease and lung cancer.Methods A total of 74 patients with coronary heart disease and lung cancer were grouped according to the odd and even numbers of admission numbers,with 37 odd numbered patients as the control group and 37 even numbered patients as the observation group.The control group received concurrent coronary artery bypass grafting combined with lung cancer resection,and the observation group received docetaxel+cisplatin chemotherapy based on the control group.The levels of tumor markers,T cell subsets,clinical efficacy,complications and survival were compared between the two groups.Results 1 week after treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCC),neuron-specific enolase(NSE),and cytokeratin fragment 19(CYFRA21-1)in both groups decreased;the observation group had CEA of(16.04±1.56)ng/ml,CA125 of(70.65±2.90)ng/ml,SCC of(7.08±1.05)ng/ml,NSE of(13.37±0.82)ng/ml and CYFRA21-1 of(11.53±1.68)ng/ml,which were lower than(22.56±2.37),(83.23±4.92),(12.09±1.43),(16.68±1.28)and(17.41±2.62)ng/ml in the control group(P<0.05).1 week after surgery,CD3+,CD4+and CD4+/CD8+in both groups were lower than those before treatment,but the observation group was higher than the control group(P<0.05).There was little difference in CD8+between and within the two groups before and after treatment(P>0.05).The total disease control rate of the observation group was 78.38%,which was higher than 54.05%of the control group(P<0.05).There was no significant difference in the incidence of postoperative complications between the two groups(P>0.05).The 6-month and 1-year survival rates of the observation group were 91.89%and 83.78%,which were higher than 72.97%and 59.46%of the control group(P<0.05).Conclusion Based on simultaneous surgery,the implementation of docetaxel+cisplatin chemotherapy in patients with coronary heart disease and lung cancer is safe and effective,which can reduce tumor marker levels,promote the improvement of immune function and survival rate in patients.
万方数据
维普
